Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).
Participants at the Susan G. Komen Breast Cancer Foundation National Race for the Cure? were among the first to view a new breast cancer ribbon today as they descended on the National Mall. More than 51,000 runners and walkers, more than including 3,500
Amylin Pharmaceuticals, Inc., and Eli Lilly and Company have presented detailed 30-week data from two of the three pivotal Phase 3 studies of exenatide during a late-breaking session
Clinicians from the McGill University Health Centre and the Centre hospitalier de l'Université de Montréal (CHUM) are participating in the first Canadian therapeutic HIV vaccine trial. Funded by a number of public and private institutions,
Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the s
A new multi-targeted anticancer drug called SU11248 has shown very promising results in the treatment for metastatic renal cell cancer, one of the most chemotherapy resistant of all cancers. The study's lead investigator, Robert Motzer, MD, attending physi
Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study presented today at the American Society of Cli
New research presented by Peter Weissman, M.D., from the University of Miami, at the 64th Annual Scientific Sessions of the American Diabetes Association shows that combination treatment with rosiglitazone maleate and metformin significantly improves ce
Patients with Type 2 diabetes and a CV risk factor would benefit from a cholesterol-lowering medicine according to results from the first ever specifically designed UK primary prevention statin trial announced today at the American Diabetes Association
Attendees at the 40th annual meeting of the Association of Clinical Oncologists were updated on the serum estrogen receptor modulator (SERM) raloxifene and the aromatase inhibitor (AI) exemestane. Newest research findings were presented on the possible
The approval follows a positive opinion granted on April 21, 2005, by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA).
The approval of Temodal in combination with radiotherapy followed by up to six cycles of Temodal monotherapy is valid in the current 25 EU Member States as well as in Iceland and Norway. The approval is based largely on efficacy and safety data from the landmark Phase III study conducted by the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trial Group.
These data were published in the March 10, 2005, edition of the New England Journal of Medicine. In this multicenter trial of 573 patients with newly diagnosed GBM, significant improvement in overall survival was observed in patients who were treated with Temodal in combination with radiotherapy compared with those treated with radiotherapy alone.
"Newly diagnosed GBM patients and their physicians now have an opportunity to combat this most aggressive brain tumor in its early stages. As demonstrated in our clinical trial, Temodal provides a significant improvement in survival compared to standard therapy," said Roger Stupp, M.D., University Hospital Multidisciplinary Oncology Centre in Lausanne, Switzerland and lead investigator of the EORTC/NCIC trial.
"It is important for patients throughout the EU to have access to this important treatment advance for this devastating disease," said Robert J. Spiegel, M.D., chief medical officer and senior vice president of medical affairs, Schering-Plough Research Institute.
The study results showed that 26 percent of the patients in the Temodal group will survive two years or longer, as compared to 10 percent for those who received radiotherapy alone, doubling the survival rate at two years. Median survival in the Temodal group was also significantly better (14.6 vs. 12.1 months) compared to the radiotherapy only group. Temodal treatment was generally well tolerated; the most commonly observed adverse events (greater than 10%) in patients receiving Temodal in combination with radiotherapy followed by Temodal monotherapy included decreased appetite, headache, constipation, nausea, vomiting, hair loss, rash, convulsions, fatigue, diarrhea, stomatitis and blurred vision. Low white blood cells and low platelets, which are known dose-limiting toxicities for most cytotoxic agents, including Temodal, were observed. When laboratory abnormalities and adverse events were combined across concomitant and monotherapy treatment phases, Grade 3 or Grade 4 neutrophil abnormalities including neutropenic events were observed in 8 percent of the patients. Grade 3 or Grade 4 thrombocyte abnormalities, including thrombocytopenic events were observed in 14 percent of the patients who received Temodal.
http://www.schering-plough.com/